Ms. hebr. oct. 89 - Mivḥar ha-peninim

Vorbesitzer: Isaachi Castelnuovo; Elia Castelnuovo; Angelo Castelnuovo; Abraham Merzbacher

Ms. Barth. 89 - In quartum Sententiarum

Vorbesitzer: Bartholomaeusstift Frankfurt am Main

Small-diameter titanium grade IV and titanium-zirconium implants in edentulous mandibles: five-year results from a double-blind, randomized controlled trial.

BACKGROUND The aim of this study was to compare the 5-year survival and success rates of 3.3 mm dental implants either made from titanium-zirconium (TiZr) alloy or from Grade IV titanium (Ti Grade IV) in mandibular implant-based removable overdentures. METHODS The core study had a follow-up period of 36 months and was designed as a randomized, controlled, double-blind, split-mouth multicenter clinical trial. Patients with edentulous mandibles received two Straumann Bone Level implants (diameter 3.3 mm, SLActive®), one of TiZr (test) and one of Ti Grade IV (control), in the interforaminal region. This follow-up study recruited patients from the core study and evaluated the plaque and sulcus bleeding indices, radiographic crestal bone level, as well as implant survival and success 60 months after implant placement. RESULTS Of the 91 patients who initially received implants, 75 completed the 36 month follow-up and 49 were available for the 60 month examination. Two patients were excluded so that a total of 47 patients with an average age of 72 ± 8 years were analysed. The characteristics and 36-month performance of the present study cohort did not differ from the non-included initial participants (p > 0.05). In the period since the 36-month follow-up examination, no implant was lost. The cumulative implant survival rate was 98.9 % for the TiZr group and 97.8 % for the Ti Grade IV group. Crestal bone level changes at 60 months were not different in the test and control group (TiZr -0.60 ± 0.69 mm and Ti Grade IV -0.61 ± 0.83 mm; p = 0.96). The cumulative implant success rate after 60 months was 95.8 and 92.6 % for TiZr and Ti Grade IV, respectively. CONCLUSIONS After 60 months, the positive outcomes of the 36 month results for TiZr and Ti Grade IV implants were confirmed, with no significant differences with regard to crestal bone level change, clinical parameters and survival or success rates. TiZr implants performed equally well compared to conventional Ti Grade IV 3.3 mm diameter-reduced implants for mandibular removable overdentures. TRIAL REGISTRATION Registered on www.clinicaltrials.gov: NCT01878331.

Small-diameter titanium Grade IV and titanium-zirconium implants in edentulous mandibles: three-year results from a double-blind, randomized controlled trial

OBJECTIVE The aim of this study was to compare crestal bone-level changes, soft tissue parameters and implant success and survival between small-diameter implants made of titanium/zirconium (TiZr) alloy or of Grade IV titanium (Ti) in edentulous mandibles restored with removable overdentures. MATERIALS AND METHODS This was a randomized, controlled, double-blind, split-mouth multicenter clinical trial. Patients with edentulous mandibles received two Straumann bone-level implants (diameter 3.3 mm), one of Ti Grade IV (control) and one of TiZr (test), in the interforaminal region. Implants were loaded after 6-8 weeks and removable Locator-retained overdentures were placed within 2 weeks of loading. Modified plaque and sulcus bleeding indices, radiographic bone level, and implant survival and success were evaluated up to 36 months. RESULTS Of 91 treated patients, 75 completed the three-year follow-up. Three implants were lost (two control and one test implant). The survival rates were 98.7% and 97.3%, and the mean marginal bone level change was -0.78 ± 0.75 and -0.60 ± 0.71 mm for TiZr and Ti Grade IV implants. Most patients had a plaque score of 0 or 1 (54% for test and 51.7% for control), and a sulcus bleeding score of 0 (46.1% for test and 44.9% for control). No significant differences were found between the two implant types for bone-level change, soft tissue parameters, survival and success. CONCLUSIONS After 36 months, similar outcomes were found between Ti Grade IV and TiZr implants. The results confirm that the results seen at 12 months continue over time.

Days spent in acute care hospitals at the end of life of cancer patients in four Swiss cantons: a retrospective database study (SAKK 89/09).

Number of days spent in acute hospitals (DAH) at the end of life is regarded as an important care quality indicator for cancer patients. We analysed DAH during 90 days prior to death in patients from four Swiss cantons. Claims data from an insurance provider with about 20% market share and patient record review identified 2086 patients as dying of cancer. We calculated total DAH per patient. Multivariable generalised linear modelling served to evaluate potential explanatory variables. Mean DAH was 26 days. In the multivariable model, using complementary and alternative medicine (DAH = 33.9; +8.8 days compared to non-users) and canton of residence (for patient receiving anti-cancer therapy, Zürich DAH = 22.8 versus Basel DAH = 31.4; for other patients, Valais DAH = 22.7 versus Ticino DAH = 33.7) had the strongest influence. Age at death and days spent in other institutions were additional significant predictors. DAH during the last 90 days of life of cancer patients from four Swiss cantons is high compared to most other countries. Several factors influence DAH. Resulting differences are likely to have financial impact, as DAH is a major cost driver for end-of-life care. Whether they are supply- or demand-driven and whether patients would prefer fewer days in hospital remains to be established.

Na 50 Nachlass Arthur Schopenhauer - 'Schopenhauer-Archiv', 89 - Brief über die Freundschaft mit Schopenhauer

veröffentlicht in: Schopenhauer, Arthur : Arthur Schopenhauers sämtliche Werke - München : Piper - Bd. 14 : Der Briefwechsel Arthur Schopenhauers ; 1 (1799 - 1849), Nr. 20;

Na 1 Nachlass Max Horkheimer, 76 - Korrespondenzen u.a. mit Hermann Igersheimer (p. II 9, 89-222c)

1 Brief und Beilage vom Institut für sozialwissenschaftliche Forschung Darmstadt an Max Horkheimer, 1949; 82 Briefe zwischen Hermann Igersheimer und Max Horkheimer, 1941-1950; 5 Briefe zwischen Harold E. Jones von der University of California und Max Horkheimer, 1947; 1 Brief von Morris Janowitz an Max Horkheimer, 1948; 2 Briefe vom Jewish Community Center an Max Horkheimer, 1948; 7 Briefe zwischen Robert P. St.John und Max Horkheimer, 1945; 2 Briefe zwischen Erich von Kahler und Max Horkheimer, 1945; 2 Briefe und Beilage zwischen Anselm Kahn und Max Horkheimer, 04.07.1945, 19.07.1945;

Na 1 Nachlass Max Horkheimer, 302 - Korrespondenzen u.a. mit Arthur Hübscher (p. V 89, 51-199)

83 Briefe und Beilagen zwischen Arthur Hübscher und Max Horkheimer, 1963-1973; 15 Briefe und Beilagen zwischen Bundesminister a. D. Ewald Bucher und Max Horkheimer, 1966-1971; 1 Brief und Beilage von Dr. Christoph Meyer an Max Horkheimer, 1969; 6 Briefe zwischen Dr. Johann Joeden und Max Horkheimer, 1966; 5 Briefe zwischen dem Oberregierungsrat Gustav Adolf Hünniger und Max Horkheimer, 1951-1953; 2 Briefe und eine Empfehlung und ein Gutachten von Edith Hünniger an Max Horkheimer, 1952-1953;

Ms. Praed. 89 - Tabula Decretalium et Sexti

Vorbesitzer: Dominikanerkloster Frankfurt am Main

Ms.Ff.F.Stoltze 3. 89 - Brief von Johann Friedrich Gerhard an Friedrich Stoltze

Persönliche Nachrichten, Stoltze, Alexander Gwinner

Ausst. 89 - Die Leidenswerkzeuge Christi, das Heilige Grab mit Magdalena und zwei Heilige

Vorbesitzer: Augustinerkloster Mariastein bei Eichstätt; Bartholomaeusstift Frankfurt am Main;

Ms. lat. qu. 89 - Pitture in S. Calisto di Roma

Vorbesitzer: Michelangelo Gualandi;